Clinical Trial Update: Study of Visilizumab Versus Placebo in Subjects With Intravenous Steroid-refractory Ulcerative Colitis Previously Responsive in a Visilizumab Study [Phase 2, Phase 3]

View source ↗

Summary

Clinical trial update indicating a terminated Phase 2/Phase 3 study comparing visilizumab to placebo in intravenous steroid-refractory ulcerative colitis.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Ulcerative Colitis

Drugs mentioned

• Visilizumab (visilizumab)

Snippet

Sponsor: Facet Biotech | Conditions: Ulcerative Colitis | Phase 2, Phase 3 | Status: TERMINATED